Now Approved
OTIPRIO™ ciprofloxacin otic suspension 6%

OTO-104

A sustained-exposure formulation of the steroid dexamethasone that has completed a Phase 2b clinical trial for patients with Ménière’s disease...
LEARN MORE »

OTO-311

A sustained-exposure formulation of the NMDA receptor antagonist gacyclidine entering Phase 1 for the treatment of tinnitus...
LEARN MORE »

OTO-4XX

Otonomy has acquired the rights to multiple product candidates for our fourth development program, which will target age-related hearing loss, also known as presbycusis....
LEARN MORE »